Eczema Clinical Trial
Official title:
Monocenter, Randomized, Intraindividual, Open Label, Exploratory Study Comparing 4 Weeks of Treatment With 453nm Blue Light With no Treatment in Patients With Eczema
Monocenter, randomized, intraindividual, open label, exploratory study comparing 4 weeks of treatment with 453nm blue light with no treatment in patients with Eczema. Patients will be screened up to 28 days before start of treatment. During the screening visit, the purpose and procedures of the study will be explained to potential patients and informed consent will be obtained. In addition, fungal superinfection of the target area will be examined using direct preparations and mycology cultures. At the baseline visit, patients with Eczema will be determined and all inclusion and exclusion criteria will be assessed. For eligible patients, two comparable treatment areas will be randomized to treatment with blue light (target area) or to serve as untreated control area. After randomization, patients will receive treatment of the target area with 3 applications per week at the investigational site for a total treatment period of 4 weeks. During those 4 weeks, safety and effectiveness assessments will be performed at weekly intervals. After end of treatment, the patients will be followed-up for another 2 weeks. In case no full resolution of adverse events occurred at the 2 week follow-up visit, a follow-up call will be performed after another 2 weeks. Treatment responses will be photo documented
Status | Completed |
Enrollment | 21 |
Est. completion date | March 2014 |
Est. primary completion date | March 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Signed and dated informed consent prior to any study-mandated procedure 2. Good health as determined by the Investigator according to physical examination 3. Willing and able to comply with study requirements 4. Skin type I-IV according to Fitzpatrick 5. Eczema, severity defined by an Eczema Area Severity Index (EASI)smaller/equal 20 6. Comparable clinical symptomatology of both intended treatment Areas 8. Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1% per year; e.g. oral contraceptives, intrauterine device [IUD] or transdermal contraceptive patch) 9. Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during the course of the study Exclusion Criteria: 1. Inmates of psychiatric wards, prisons, or other state institutions 2. Investigator or any other team member involved in the conduct of the clinical study 3. Participation in another clinical trial within the last 30 days 4. Pregnant and lactating women 5. Photodermatosis and/or Photosensitivity 6. Porphyria and/or hypersensitivity to porphyrins 7. Congenital or acquired immunodeficiency 8. Patients with any of the following conditions present on the study areas; Malignoma of the skin or severe actinic damage of the skin, atypical naevi or signs of hyperpigmentation, precancerosis viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin 9. Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom- Syndrome) 10. Current diagnosis of exfoliative or toxic dermatitis. 11. Evidence of superinfection of the intended treatment areas |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Klinik for Dermatology and Allergology, medical faculty of the RWTH Aachen | Aachen | NRW |
Lead Sponsor | Collaborator |
---|---|
Light and Health Venture |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Hyperpigmentation - Evaluation by Mexameter | Higher values describe a higher level of pigmentation. | week 0, 2, 4, 6 | Yes |
Other | Adverse Events (Serious and Non-serious) | week 0, 2, 4, 6 | Yes | |
Other | Adverse Device Events (Serious and Non-serious) | over 6 weeks | Yes | |
Other | Device Deficiencies | This measure describes device deficiencies in general leading to a non functional device. No specific characteristics were assessed. | over 6 weeks | Yes |
Other | Recovery of Hyperpigmentation During Follow up Period (Compared to Last Treatment) | Higher values describe a higher level of pigmentation. | week 6 | Yes |
Other | Number of Participants With Acceptance of Hyperpigmentation at Week 6 | Questionaire if hyperpigmentation was acceptable if reported. Outcome was number of patients answering "yes" or "no". | week 6 | Yes |
Primary | Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment | The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)). | at week 4 | No |
Secondary | Change From Week 4 of the Sum Score of Local Eczema Rating as Compared to the Control Area at End of Follow-up | The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)). | week 6 | No |
Secondary | Change From Baseline of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area | Higher values describe higher erythema levels. | week 4, 6 | Yes |
Secondary | Change From Week 4 (End of Treatment) of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area at End of Follow-up | Higher values describe a higher level of erythema. | week 6 | Yes |
Secondary | Change From Baseline of Patient Rating of Itching of the Target Area as Compared to the Control Area | patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching) | week 4, 6 | No |
Secondary | Change From Week 4 (End of Treatment) of Patient Rating of Itching of the Target Area as Compared to the Control Area at End of Follow-up | patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching). | week 6 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01257061 -
Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment
|
Phase 3 | |
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Withdrawn |
NCT03089476 -
Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy
|
N/A | |
Recruiting |
NCT04818138 -
BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort
|
N/A | |
Recruiting |
NCT05439577 -
A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
|
||
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Completed |
NCT02075632 -
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
|
Phase 2 | |
Completed |
NCT00143819 -
Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
|
Phase 2 | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT04358224 -
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
|
Phase 4 | |
Not yet recruiting |
NCT04520308 -
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis
|
Phase 4 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT04023084 -
Response of Children With Atopic Dermatitis (Eczema) to Eucrisa
|
Phase 4 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Completed |
NCT05583019 -
Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
|
||
Completed |
NCT03293030 -
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
|
Phase 4 | |
Completed |
NCT01420705 -
Bacille Calmette-Guérin (BCG) Vaccine and Atopy
|
N/A | |
Recruiting |
NCT01012453 -
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
|
N/A | |
Completed |
NCT00375713 -
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
|
Phase 3 | |
Recruiting |
NCT00177268 -
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
|